Clinical Trial Details
| Trial ID: | L4750 |
| Source ID: | NCT03051243 |
| Associated Drug: | Linagliptin And Basal Insulin |
| Title: | Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | DM2 |
| Interventions: | DRUG: Linagliptin and Basal Insulin|DRUG: Basal Insulin and Bolus Insulin |
| Outcome Measures: | Primary: Percentage of patient with mean blood glucose levels, between 80-180 mg/dl., After firts day from admission and Up to 14 days, 3 and 6 month after discharge. | Secondary: Difference in BG values within range, 140-180 mg/dl., After firts day from admission and Up to 14 days, 3 and 6 month after discharge|Number of hypoglycemic events (BG <70 and or < 40 mg/dL)., \<70 and or \< 40 mg/dL, After firts day from admission and Up to 14 days, 3 and 6 month after discharge|Number of episodes of hyperglycemia, \>240 mg/dL, After firts day from admission and Up to 14 days, 3 and 6 month after discharge|TTD (total daily dose) of insulin, units of insulin, After firts day from admission and Up to 14 days, 3 and 6 month after discharge |
| Sponsor/Collaborators: | Sponsor: Rabin Medical Center |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 60 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2017-10-01 |
| Completion Date: | 2019-11-01 |
| Results First Posted: | |
| Last Update Posted: | 2017-09-11 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT03051243 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|